Project Details

Early Career

Status: Funded - Open

Extending therapeutic efficacy studies to improve surveillance for drug- and diagnostic-resistant malaria in Ethiopia

Ashenafi Bahita, PhD


BACKGROUND: Diagnosis and treatment are key components of malaria control; however, the Ethiopia National Malaria Control Program (NMCP)have limited advanced laboratory infrastructure required to conduct molecular surveillance for markers of key antimalarial drug and diagnostic resistance mutations. Molecular determination of drug resistance and pfhrp2/3 deletion prevalence performed in this study will provide key inputs for the NMCP in Ethiopia and the global malaria community. GAP: Incomplete understanding of the true prevalence of antimalarial drug resistance and pfhrp2/3 deletions are knowledge gaps required by the NMCP to make informed policy decisions. HYPOTHESIS: The study hypothesizes low prevalence of antimalarial drug resistance markers and high prevalence of pfhrp2/3 deletions in the study sites, based on our prior work and surveillance data from neighboring countries METHODS: Extracted DNA will be used for multiplex amplicon deep sequencing, targeting known markers of antimalarial drug resistance; and pfhrp2/3 deletion genotyping using a multiplex real-time PCR assay. RESULTS: Pending. IMPACT: The study outcome will be used by the NCMP to further determine antimalarial drug and malaria diagnostic testing policy, so as supporting the fight against malaria that is disproportionately affecting children and pregnant women. Website Link: